SLC5A2 and type 2 diabetes mellitus: Based on the available evidence, bexagliflozin appears to be a safe and effective treatment for T2D; however, there is no high-quality evidence supporting the use of bexagliflozin over other SGLT-2 inhibitors in clinical practice.